文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

欧洲呼吸机相关性肺炎临床与微生物流行病学的持续观察性研究

Perpetual observational study of the clinical and microbiological epidemiology of ventilator-associated pneumonia in Europe.
PubMed 文献 · Crit Care · 2026-03-12
一句话结论欧洲11国25个ICU前瞻性研究显示VAP累积发生率17.1%、ICU死亡率34.2%,以甲氧西林敏感金黄色葡萄球菌最常见。

该研究为Ecraid网络开展的前瞻性持续观察性研究,2022年8月至2024年9月纳入11个欧洲国家25个ICU中预期有创机械通气≥48小时的成人患者。3446例VAP风险患者中590例发生VAP,累积发生率17.1%(95%CI 15.9%-18.4%),每1000个通气日发生率18.6(95%CI 17.1-20.1),国家间差异大(7.6%-29.6%)。359例(60.8%)有微生物学证据,以金黄色葡萄球菌(26.2%)、流感嗜血杆菌(16.2%)和铜绿假单胞菌(15.0%)为主。VAP患者ICU死亡累积发生率34.2%,高于非VAP患者的29.3%;首次拔管前中位有创通气时间17天 vs 7天。

要点

  • 3446例有创机械通气≥48小时成人中590例发生VAP,累积发生率17.1%(95%CI 15.9%-18.4%),每1000通气日18.6(95%CI 17.1-20.1)。
  • 招募≥100例患者国家间VAP累积发生率差异大,范围7.6%(克罗地亚)至29.6%(罗马尼亚)。
  • 359例(60.8%)VAP有微生物学证据,最常见为金黄色葡萄球菌26.2%、流感嗜血杆菌16.2%、铜绿假单胞菌15.0%。
  • VAP患者ICU死亡累积发生率34.2%(95%CI 30.4%-38.0%),非VAP患者29.3%(95%CI 27.6%-30.9%);首次拔管前中位有创通气时间17天 vs 7天。
  • 最广泛实施的VAP预防措施为床头抬高(3207例,93.1%),仅4例(0.1%)未实施任何预防措施。

适用人群与场景

  • 11个欧洲国家25个ICU中预期有创机械通气至少48小时的成人患者,2022年8月至2024年9月前瞻性纳入。
  • 随访至ICU出院或VAP诊断后28天。

诊断标准与关键阈值

  • VAP定义依据美国食品药品监督管理局(US Food and Drug Administration)指南。

研究设计与关键结果

  • 研究类型:前瞻性持续观察性研究;样本量3446例VAP风险患者,来自11个欧洲国家25个ICU。
  • 主要终点:590例发生VAP,累积发生率17.1%(95%CI 15.9%-18.4%),每1000通气日发生率18.6(95%CI 17.1-20.1)。
  • 国家间异质性:招募至少100例患者的国家中,VAP累积发生率范围7.6%(克罗地亚)至29.6%(罗马尼亚)。
  • 微生物学:359例(60.8%)有微生物学证据,金黄色葡萄球菌26.2%、流感嗜血杆菌16.2%、铜绿假单胞菌15.0%。
  • 耐药:77例金黄色葡萄球菌VAP中14例(18.2%)确认甲氧西林耐药;铜绿假单胞菌对头孢他啶耐药10/46例(21.7%),对碳青霉烯类耐药8/47例(17.0%)。
  • 临床结局:VAP患者ICU死亡累积发生率34.2%(95%CI 30.4%-38.0%),非VAP患者29.3%(95%CI 27.6%-30.9%);首次拔管前中位有创通气时间VAP患者17天(包括诊断前后通气),非VAP患者7天。
  • 预防措施:床头抬高最广泛实施(3207例,93.1%);仅4例(0.1%)未实施任何预防措施。

证据类型、等级与局限

  • 证据类型:前瞻性持续观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为VAP与不良临床预后相关,强调需要更好的VAP预防和管理策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The clinical and microbiological epidemiology of ventilator-associated pneumonia (VAP) is not well studied in intensive care units (ICUs) European wide. The European Clinical Research Alliance on Infectious Diseases (Ecraid), a warm-base clinical research network investigating infectious diseases, aimed to track the implementation of VAP prevention strategies and quantify the incidence, aetiology, and clinical outcome of VAP, across several European countries. METHODS: Overall, 25 ICUs from 11 European countries participating in Ecraid’s perpetual observational study prospectively enrolled adult patients with an expected length of invasive mechanical ventilation (IMV) of at least 48 h, between August 2022 and September 2024. VAP was defined according to the US Food and Drug Administration guidelines. Patients were followed until ICU discharge or 28 days after VAP diagnosis. Routine clinical and microbiological data were prospectively collected. Mortality was calculated using cumulative incidence functions. RESULTS: Of the 3,446 patients at-risk of VAP, 590 developed VAP (cumulative incidence: 17.1%, 95% CI 15.9%-18.4% and incidence rate per 1000 ventilator days: 18.6, 95% CI 17.1–20.1). Importantly, VAP cumulative incidence varied widely between countries recruiting at least 100 patients (range: 7.6% (Croatia)-29.6% (Romania)). Microbiological documentation was available for 359 (60.8%) VAP patients, predominantly showing Staphylococcus aureus (26.2%), Haemophilus influenzae (16.2%), and Pseudomonas aeruginosa (15.0%). Methicillin resistance was confirmed in 14 (18.2%) of 77 VAP cases due to S. aureus. Ceftazidime and carbapenem resistance for P. aeruginosa was reported in 10/46 (21.7%) and 8/47 (17.0%) cases, respectively. Cumulative incidence of ICU mortality was 34.2% (95% CI 30.4%-38.0%) among VAP patients versus 29.3% (95% CI 27.6%-30.9%) in non-VAP patients. The overall median IMV duration until first extubation was 17 days in VAP patients (including ventilation before and after diagnosis) versus 7 days for non-VAP patients. The most widely implemented VAP prevention measure was head-of-bed elevation (3207 patients, 93.1%); only 4 patients (0.1%) did not have any prevention measures implemented. CONCLUSION: In European ICUs, there is a considerable and heterogeneous incidence of VAP, with methicillin susceptible S. aureus most frequently identified as a causative pathogen. VAP is associated with poor clinical prognosis, highlighting the need for better VAP prevention and management strategies.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Jackson H, Hernandez Padilla AC, Vintcent LEM, et al. Perpetual observational study of the clinical and microbiological epidemiology of ventilator-associated pneumonia in Europe. Crit Care. 2026. PMID: 41821089. doi:10.1186/s13054-025-05753-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。